Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00NAX
|
||||
| Former ID |
DAP000430
|
||||
| Drug Name |
Promazine
|
||||
| Synonyms |
Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Moderate and severe psychomotor agitation | Approved | [1] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Wyeth Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H20N2S
|
||||
| InChI |
InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
|
||||
| InChIKey |
ZGUGWUXLJSTTMA-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 58-40-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9583, 90371, 647046, 5236626, 7980397, 8153033, 10525853, 10528271, 11111651, 11111652, 11335594, 11360833, 11363760, 11366322, 11368884, 11372094, 11374833, 11377046, 11461805, 11466721, 11467841, 11484533, 11486502, 11488655, 11490833, 11492962, 11494680, 14848900, 29224004, 46504504, 47216716, 47216717, 47291075, 47365121, 47440189, 47515258, 47588936, 47959671, 47959672, 48416476, 49698885, 50006482, 50100325, 50104276, 50686916, 56352878, 57288820, 57322527, 85209395, 90341344
|
||||
| ChEBI ID |
ChEBI:8459
|
||||
| SuperDrug ATC ID |
N05AA03
|
||||
| SuperDrug CAS ID |
cas=000058402
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M5 | Target Info | Binder | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.